Julien Vouillarmet1, Myriam Moret2, Isabelle Morelec3, Paul Michon4, Julien Dubreuil3. 1. Hospices Civils de Lyon, Service d'Endocrinologie, Diabète et Obésité, Centre Hospitalier Lyon-Sud, 69495, Pierre Bénite, France. julien.vouillarmet@chu-lyon.fr. 2. Hospices Civils de Lyon, Service d'Endocrinologie et Diabète, Groupement Hospitalier Est, Bron, France. 3. Hospices Civils de Lyon, Service de Médecine Nucléaire, Centre Hospitalier Lyon-Sud, Pierre Bénite, France. 4. Hospices Civils de Lyon, Service d'Endocrinologie, Diabète et Obésité, Centre Hospitalier Lyon-Sud, 69495, Pierre Bénite, France.
Abstract
AIMS/HYPOTHESIS: Diabetic foot osteomyelitis is a major risk factor for amputation. Medical treatment allows remission in 53-82% of cases. However, the optimal duration of antibiotic therapy remains controversial as a validated marker of osteomyelitis remission is lacking. The aim of this cohort study was to assess prospectively the remission rate of diabetic foot osteomyelitis medically treated using white blood cell (WBC)-single-photon emission computed tomography (SPECT)/computed tomography (CT) as a predictive marker of remission. METHODS: Individuals with diabetic foot osteomyelitis that was non-surgically treated between April 2014 and December 2015 were included. All participants were treated with antibiotics alone. WBC-SPECT/CT was performed at 6 weeks and antibiotic treatment discontinued if the clinical signs of soft-tissue infection had resolved and there was no abnormal uptake of labelled WBCs. Treatment was otherwise continued for a total of 12 weeks and then discontinued. For these individuals, another WBC-SPECT/CT was performed at 12 weeks. Remission was defined as the absence of recurrence of osteomyelitis at the same location at 1 year. RESULTS: Forty-five individuals were included; overall remission rate was 84% at 1 year. A 6 week course of antibiotics was used in 23 participants, 22 of whom were in remission at 1 year (96%); a 12 week course was used for 22 participants, 16 of whom were in remission at 1 year (73%). Sensitivity of WBC-SPECT/CT at 12 weeks was 100%, specificity 56%, positive predictive value 46% and negative predictive value 100%. CONCLUSIONS/ INTERPRETATION: The study suggests that WBC-SPECT/CT could predict remission at the end of antibiotic treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT02927678.
AIMS/HYPOTHESIS: Diabetic foot osteomyelitis is a major risk factor for amputation. Medical treatment allows remission in 53-82% of cases. However, the optimal duration of antibiotic therapy remains controversial as a validated marker of osteomyelitis remission is lacking. The aim of this cohort study was to assess prospectively the remission rate of diabetic foot osteomyelitis medically treated using white blood cell (WBC)-single-photon emission computed tomography (SPECT)/computed tomography (CT) as a predictive marker of remission. METHODS: Individuals with diabetic foot osteomyelitis that was non-surgically treated between April 2014 and December 2015 were included. All participants were treated with antibiotics alone. WBC-SPECT/CT was performed at 6 weeks and antibiotic treatment discontinued if the clinical signs of soft-tissue infection had resolved and there was no abnormal uptake of labelled WBCs. Treatment was otherwise continued for a total of 12 weeks and then discontinued. For these individuals, another WBC-SPECT/CT was performed at 12 weeks. Remission was defined as the absence of recurrence of osteomyelitis at the same location at 1 year. RESULTS: Forty-five individuals were included; overall remission rate was 84% at 1 year. A 6 week course of antibiotics was used in 23 participants, 22 of whom were in remission at 1 year (96%); a 12 week course was used for 22 participants, 16 of whom were in remission at 1 year (73%). Sensitivity of WBC-SPECT/CT at 12 weeks was 100%, specificity 56%, positive predictive value 46% and negative predictive value 100%. CONCLUSIONS/ INTERPRETATION: The study suggests that WBC-SPECT/CT could predict remission at the end of antibiotic treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT02927678.
Authors: Francisco Lazaga; Suzanne Av Van Asten; Adam Nichols; Kavita Bhavan; Javier La Fontaine; Orhan K Oz; Lawrence A Lavery Journal: Int Wound J Date: 2015-04-08 Impact factor: 3.315
Authors: John M Embil; Greg Rose; Elly Trepman; Mary Cheang M Math; Frank Duerksen; J Neil Simonsen; Lindsay E Nicolle Journal: Foot Ankle Int Date: 2006-10 Impact factor: 2.827
Authors: Javier La Fontaine; Kavita Bhavan; Kenrick Lam; Suzanne Van Asten; William Erdman; Lawrence A Lavery; Orhan K Öz Journal: Wounds Date: 2016-08 Impact factor: 1.546
Authors: Elisabeth Aslangul; Jocelyne M'bemba; Nadine Caillat-Vigneron; Sophie Coignard; Etienne Larger; Christian Boitard; Benjamin A Lipsky Journal: Diabetes Care Date: 2013-03-20 Impact factor: 19.112
Authors: Lawrence A Lavery; P Andrew Crisologo; Javier La Fontaine; Kavitha Bhavan; Orhan K Oz; Kathryn E Davis Journal: J Foot Ankle Surg Date: 2019-07 Impact factor: 1.286
Authors: Ora Israel; O Pellet; L Biassoni; D De Palma; E Estrada-Lobato; G Gnanasegaran; T Kuwert; C la Fougère; G Mariani; S Massalha; D Paez; F Giammarile Journal: Eur J Nucl Med Mol Imaging Date: 2019-07-04 Impact factor: 9.236
Authors: Katie Rubitschung; Amber Sherwood; Andrew P Crisologo; Kavita Bhavan; Robert W Haley; Dane K Wukich; Laila Castellino; Helena Hwang; Javier La Fontaine; Avneesh Chhabra; Lawrence Lavery; Orhan K Öz Journal: Int J Mol Sci Date: 2021-10-26 Impact factor: 5.923